Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.
Publication
, Conference
Armstrong, AJ; Saad, F; Shore, ND; Fizazi, K; Phung, D; Dmuchowski, C; Hirmand, M; Forer, D; Scher, HI; De Bono, JS
Published in: Journal of Clinical Oncology
May 20, 2016
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2016
Volume
34
Issue
15_suppl
Start / End Page
5062 / 5062
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J., Saad, F., Shore, N. D., Fizazi, K., Phung, D., Dmuchowski, C., … De Bono, J. S. (2016). Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM. In Journal of Clinical Oncology (Vol. 34, pp. 5062–5062). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.5062
Armstrong, Andrew J., Fred Saad, Neal D. Shore, Karim Fizazi, De Phung, Carl Dmuchowski, Mohammad Hirmand, David Forer, Howard I. Scher, and Johann S. De Bono. “Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.” In Journal of Clinical Oncology, 34:5062–5062. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.5062.
Armstrong AJ, Saad F, Shore ND, Fizazi K, Phung D, Dmuchowski C, et al. Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 5062–5062.
Armstrong, Andrew J., et al. “Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 5062–5062. Crossref, doi:10.1200/jco.2016.34.15_suppl.5062.
Armstrong AJ, Saad F, Shore ND, Fizazi K, Phung D, Dmuchowski C, Hirmand M, Forer D, Scher HI, De Bono JS. Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 5062–5062.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2016
Volume
34
Issue
15_suppl
Start / End Page
5062 / 5062
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences